Spiradenoma

Last updated
Spiradenomas
Other namesEccrine spiradenoma
Eccrine spiradenoma - very low mag.jpg
Micrograph of a spiradenoma (bottom-center of image). H&E stain.
Specialty Dermatology, Surgery, Oncology
Symptoms Solitary skin tumor
Risk factors development of malignant tumors

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated (i.e. matured from stem cells) towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. [1] SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors [2] and commonly term them spiradenomas and spiradenocarcinomas, respectively. [2] [3] Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. [4] Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

Contents

SA tumors usually occur as slow-growing, [5] single, small, nodular lesions located in the skin of the head, neck, or trunk. [3] SAC tumors develop from benign SA tumors or in very rare cases begin as malignant tumors. [6] SA and SAC tumors must be distinguished from the spiradenoma and spiradenocarcinoma tumors that develop in individuals afflicted with the CYLD cutaneous syndrome. CCS is an inherited disorder that commonly involves the development of multiple but on occasion a single or few tumors that closely resemble, and may be confused with, the sporadic SA and SAC tumors described here. [4] [7] [8] CCS spiradenoma and CCS spiradenocarcinoma tumors must be distinguished form the sporadic SA and SAC tumors reviewed here in order to afford genetic counseling to individuals with CCS as well as to the close family members of these individuals. [9]

Currently, SA [3] and SAC [5] are usually treated by complete excision making sure that no tumor cells are left behind at the surgical site. This is particularly important in SAC where the incomplete surgical removal of all tumor cells may result in recurrence of the tumor at the surgical site and/or its metastasis to the local lymph nodes draining the surgical site and/or to distant tissues. [5] In addition to surgical resection, some cases of SAC tumors have been treated with adjuvant therapy that includes radiotherapy and/or chemotherapy. [6] It is not clear that these adjuvant treatments improve patient prognoses. Further studies are needed to determine the best treatment(s) for localize SA, localized SAC, and, in particular, metastatic SAC tumors. [5]

Presentation

Spiradenoma tumors occur in individuals of various ages but tend to develop in middle-aged and elder adults (e.g. in a study of 27 patients, the median age at diagnosis was 62 years). [2] However, cases have been reported in children as young as 2 years. [10] These tumors usually present as a solitary, sometimes painful, [11] slowly growing, 1–2 cm (i.e. centimeters), gray-to-pink nodules that lie underneath the skin's epidermis in the head, neck, trunk, arms, or legs. [12] However, these nodules have been reported to be as large as 6 cm [11] and to occur in other hair follicle-containing cutaneious sites such as the vulva, [13] breast, and breast nipple. [14] Areas of the skin that do not have hair follicles (e.g. palms of the hands and soles of feet) do not develop these nodules. [11] Less than 2% of cases present with more than one nodule; the multiple nodules in SA tend to array in a linear, blaschkoid (i.e. V-, U-, or inverted U-shaped), or zosteriform (i.e. belt- or girdle-shape tracking an area of skin served by a sensory nerve) patterns. [12] Giant vascular eccrine spiradenomas are larger (> 2 cm) and more highly vascular variants of SA that usually develop at the same cutaneous sites as SA but have also been reported to occur in the abdomen and scrotum. No malignant giant vascular SA has been described in the literature to date (2021). [12]

A recent review of 182 cases reported that spiradenocarcinomas were diagnosed in individuals 8–89 years old (mean 57.4 years). These SAC tumors developed in SA tumors that had existed for 0–720 months (mean 168.5 months); 14.4% of individuals were diagnosed with multiple carcinoma lesions. (Multiple SAC lesions may appear as a nodule associated with smaller satellite nodules. [6] ) The lesions occurred on the trunk (32.3% of cases), limbs (31.3%), head or neck (30.7%), and genitalia (1.6%). These individuals presented with lesions that began to show abnormal growth (82.6% of cases), pain (47.7% of cases), and/or ulcerations (38.7% of cases). [5] In earlier studies, SAC tumors were reported to varied in size with 40% being larger than 5 cm and the majority not having metastasized; the sites to which these lesions metastasized were most commonly to lymph nodes near to the SAC or, rarely, distant tissues such as the lung, liver, brain, spinal cord, bone, skin, and breast. [6] [15] [16]

Pathology

As determined by the microscopic histopathological appearances of their hematoxylin and eosin-stained samples, spiradenomas are non-encapsulated nodular skin lesions that extend into the dermis. The lesions consist of a relatively disorganized and dense array of proliferating basophilic cells (i.e. cells appearing blue because of their abnormally large uptake of the hematoxylin stain). [9] These cells are arranged as small cells with hyperchromatic nuclei and scant cytoplasm layered outside and larger cells with vesicular (i.e. vesicle-containing) nuclei layered inside of intertwining strips. [16] Lymphocytes commonly populate these lesions. Some lesions may merge the histopathological features of spiroadenomas with those of cylindromas. [9] Cylindromas are hair follicle tumors that consist of basal cells (i.e. small, round cells similar to those seen in the lowest layer of the skin's epidermis) which are arranged in ("jigsaw-like" [17] cylindrical patterns separated by thickened basement membranes. The cylindroma tissues may also contain disorganized, dense arrays of proliferating basophilic cells. [9]

Spiradenocarcinoma tumors almost always derive from SA tumors [18] and have areas of SA architecture abruptly transitioning to areas of SAC architecture. The SAC component of these lesions consists of cells that, along with their nuclei and cytoplasm, vary greatly in size and shape. The cells may be rapidly proliferating, have atypical mitosis figures, and may be invading nearby neural or lymphovascular structures; they do not arrange into intertwining strips of small and large cells. [16] High-grade SAC tissues show a more severely disturbed architecture, more marked variation in cell, nuclei, and cytoplasm sizes and shapes, and more rapidly proliferating cells than low-grade SAC tissues. [19] SAC tumor tissues may show various other features, e.g. they may closely resemble sarcomas. [19] In rare cases, SAC has been reported to apparently arise de novo, i.e. begin as malignant lesions. [18]

Gene abnormalities

Studies indicate that a minority of SA and SAC cases have one of two potentially disease-causing mutations in their tumor cells: loss-of-function (i.e. gene-inactivating) mutations in the CYLD gene in 5 of 17 SA and 2 of 24 SAC cases or gain-of-function (i.e. gene-activating) mutations in the ALPK1 gene in 7 of 16 SA and 4 of 14 SAC cases. The two mutations are mutually exclusive, i.e. do not occur together in any individual's tumor(s). [20] Both mutations result in blocking the actions of NF-κB. [20] [17] NF-κB is a transcription factor which acts indirectly to stimulate the expression of various genes that trigger cell death by apoptosis and necroptosis [21] and also inhibit cell proliferation (see CYLD gene's mechanism of action). [22] It is proposed that the blockade of NF-κB's actions prolongs cell survival, stimulates high rates of cell growth, and perhaps has other effects which contribute to the formation and/or progression of SA and SAC tumors. [9] [23]

Diagnosis

SA and SAC tumors have been confused with leiomyoma, angiolipoma, granular cell tumor, [11] basal cell carcinoma, squamous cell carcinoma, metastatic adenocarcinoma, and adenoid cystic carcinoma tumors; [19] the giant vascular SA form of these tumors has been mistaken for a hemangioma, angiolipoma, calcifying epithelioma, neuroma, malignant melanoma, angiosarcoma, vascular malformation, and venous thrombosis. [12] CT scans, FDG-positron emission tomography, and magnetic resonance imaging to detect 1) the shape and local invasiveness of these tumors and 2) the presence of metastases [5] and 2) the clinical presentation of individuals of these tumors often suggest the correct diagnosis. However, definitive separation of SA, SAC, and giant vascular SA from the just cited lesions requires histopathological examinations. [11] [17] The diagnosis of SA versus SAC tumors is often suggested by their clinical presentations, e.g. rapid enlargement or onset of pain in a long-standing SA tumor strongly suggests that it has become a SAC. [16] Findings that a known SA or undiagnosed tumor has areas of SA histology transitioning to SAC histology (see above Pathology section) is virtually diagnostic for SAC. [19]

The sporadic SA and SAC tumors reviewed here must also be distinguished from the very similar appearing SA-like and SAC-like tumors in individuals afflicted with the CYLD cutaneous syndrome. CCS is a familial disease uniformly associated with the inheritance of inactivating mutations in the CYLD gene. Individuals with CCS commonly develop an increasingly large number of skin tumors, including SA and SAC, over time. Usually, these individuals are readily distinguished from sporadic SA and SAC by their family history of the disease and the presence of large numbers of tumors. The rare cases of CCS that present with one or a few tumors are distinguished form CCS by testing for the CYLD gene: all individuals with CCS carry a mutated CYLD gene in their tumor as well as other tissues such as blood leucocytes while individuals with sporadic SA or SAC carry the mutated CYLD gene in their tumor but not other tissues (see Genetics of CCS). It is important to afford individuals with CCS and the close family members of these individuals access to in depth genetic counselling. [9]

Treatments

There is no consensus on the best treatment(s) for SA and SAC tumors. Further research, including meta-analysis comparisons of different treatment regimens, is needed to define the best treatment(s) for these tumors. In all cases, however, regular follow-ups of individuals with SA and SAC are strongly recommended in order to detect as early as possible: the formation of new tumors; changes in old tumors that suggest their progression to more aggressive or malignant forms; local recurrences of surgically removed tumors; and the development of local or distant metastases. [5] [11] One recommended follow-up strategy prescribes patients to have check-ups every three months in the first year after treatment, every six months in the second year after treatment, and annually thereafter. Each check-up should incorporate the examination of the patients' regional lymph nodes and on a case-by-case basis annual chest X-rays and liver function tests. [5]

Spiradenomas

The currently preferred treatment for sporadic SA tumors (including giant vascular eccrine SA) in almost all cases is surgical excision. [5] Many studies recommend wide local surgical excision of these tumors with surgical margins of ≥1 cm in order to ensure that all tumor cells are removed: local lymph node resections are usually reserved for those cases suspected of having lymph node metastases. [5] [6] [12] Mohs micrographic surgery has been used as an alternative to surgical excision for the complete removal of these tumors. [6] Since SA tumors may contain unidentified areas of malignancy and therefore have high recurrence rates, may metastasize to local lymph nodes and/or distant tissues, and can result in overall poor survival times, [16] adjuvant radiation therapy has been used to minimize these aggressive events in SA tumors with equivocal signs of malignancy. However, the effectiveness of these adjuvant therapies has not been established. [6] Adjuvant CO2 laser treatments have been used on occasion to remove these tumors in cases with multiple tumors. [3] Some trials have using botulinum toxin A and triamcinolone injections directly into SA tumors [10] but these trials have had limited success. [11]

Spiradenocarcinomas

With only 117 malignant cases reported in the literature as of 2022, there are no standard guidelines for the treatment of SAC tumors. [24] Localized (i.e. no evidence of metastases) SAC tumors and SAC tumors that have metastasized to local lymph nodes are commonly treated by surgical removal (with ≥1 cm margins) of the tumor plus surgical resection (i.e. removal) of the local lymph nodes. Individuals presenting with lymph node metastasis have also been treated with one or both of theses regimens plus, where possible and indicated, adjuvant radiation therapy to the areas of the removed tumors and lymph nodes. [5] Chemotherapeutic agents such as methotrexate, cisplatin, etoposide, and 5-fluorouracil have been used to treat SAC with distant tissue metastases but the success of these drug treatments has been limited. [6]

Prognoses

In the only meta-analysis study reported on the treatment of SA and SAC tumors to date, 35 individuals with SA tumors and no evidence of local or distant metastasis who were treated with local resection (3 of these individuals underwent additional lymph node resections after removal of their primary tumor) all 35 were disease-free with a mean follow-up period of 33 months. Among individuals with SAC tumors that had metastasized to lymph nodes but not distant tissues, 3 individuals who had surgical excisions of their tumors but not their involved lymph nodes died of metastatic disease (range 39–49 months, mean survival range 45 months); one individual was alive with disease 24 months after lymph node dissection; and 8 individuals (6 of whom had lymph node dissection) lacked evidence of recurrent disease (observation times 2 to 97 months, mean observation time 47 months). [6] In a review of 136 reported cases treated for SA or SAC: 1) 4.4% and 14.7% of individuals with SA and SAC tumors, respectively, had died (time between treatment and death was not reported); 2) patients who presented with metastasis to distant tissues had a median survival time of 16 months (11 of these patients were treated with adjuvant therapy in addition to surgery [adjuvant treatments included 5 patients treated with radiotherapy, 3 treated with chemotherapy, and 2 treated with both radiotherapy and chemotherapy]); and 3) Surgery with adjuvant therapy yielded a median survival time of 20 months (this survival time did not significantly differ from that found in individuals treated with surgery alone). [5]

See also

Related Research Articles

<span class="mw-page-title-main">Melanoma</span> Skin cancer originating in melanocytes

Melanoma is the most dangerous type of skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye. In women, melanomas most commonly occur on the legs; while in men, on the back. Melanoma is frequently referred to as malignant melanoma. However, the medical community stresses that there is no such thing as a 'benign melanoma' and recommends that the term 'malignant melanoma' should be avoided as redundant.

<span class="mw-page-title-main">Anaplastic large-cell lymphoma</span> Medical condition

Anaplastic large-cell lymphoma (ALCL) refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. Considered as a single entity, ALCL is the most common type of peripheral lymphoma and represents ~10% of all peripheral lymphomas in children. The incidence of ALCL is estimated to be 0.25 cases per 100,000 people in the United States of America. There are four distinct types of anaplastic large-cell lymphomas that on microscopic examination share certain key histopathological features and tumor marker proteins. However, the four types have very different clinical presentations, gene abnormalities, prognoses, and/or treatments.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Hidradenoma</span> Medical condition

Hidradenoma refers to a benign adnexal tumor of the apical sweat gland. These are 1–3 cm translucent blue cystic nodules. It usually presents as a single, small skin-colored lesion, and may be considered closely related to or a variant of poromas. Hidradenomas are often sub-classified based on subtle histologic differences, for example:

<span class="mw-page-title-main">Dermal cylindroma</span> Medical condition

In dermatologic pathology, a dermal cylindroma, also dermal eccrine cylindroma or cutaneous cylindroma) and cylindroma, is a benign adnexal tumor that occurs on the scalp and forehead.

<span class="mw-page-title-main">Marginal zone lymphoma</span> Group of lymphomas

Marginal zone lymphomas, also known as marginal zone B-cell lymphomas (MZLs), are a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. Marginal zone B cells are innate lymphoid cells that normally function by rapidly mounting IgM antibody immune responses to antigens such as those presented by infectious agents and damaged tissues. They are lymphocytes of the B-cell line that originate and mature in secondary lymphoid follicles and then move to the marginal zones of mucosa-associated lymphoid tissue (MALT), the spleen, or lymph nodes. Mucosa-associated lymphoid tissue is a diffuse system of small concentrations of lymphoid tissue found in various submucosal membrane sites of the body such as the gastrointestinal tract, mouth, nasal cavity, pharynx, thyroid gland, breast, lung, salivary glands, eye, skin and the human spleen.

<span class="mw-page-title-main">Malignant acrospiroma</span> Medical condition

Malignant acrospiroma, also known as nodular hidradenocarcinoma, malignant nodular clear-cell hidradenoma, mucoepidermoid hidradenocarcinoma, clear-cell hidradenocarcinoma, malignant clear-cell acrospiroma, and clear-cell eccrine carcinoma, is a rare and aggressive tumour of the eccrine sweat glands. It was first documented by Keasbey and Hadley in 1954.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Malignant tumor of oil glands in the skin

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma, is an uncommon malignant cutaneous (skin) tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Syringocystadenoma papilliferum</span> Medical condition

Syringocystadenoma papilliferum is a rare non-malignant adnexal neoplasm that develops from apocrine or eccrine sweat glands and can be identified histologically by cystic, papillary, and ductal invaginations into the dermis lined by double-layered outer cuboidal and luminal high columnar epithelium and connected to the epidermis.

Lennert lymphoma, also termed lymphoepithelioid lymphoma, lymphoepithelioid variant of peripheral T-cell lymphoma, and epithelioid cellular lymphogranulomatosis, is a rare subtype of the T cell lymphomas. It was first characterized by Karl Lennert in 1952 as a variant of Hodgkin lymphoma based on the presence of cells resembling the Reed–Sternberg cells that typify Hodgkin lymphoma. However, later studies concluded that these cells are not Reed-Sternberg cells and that Lennert lymphoma is not a variant of Hodgkin lymphoma.

<span class="mw-page-title-main">Poroma</span>

Poromas are rare, benign, cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Poromas are eccrine or apocrine sweat gland tumors derived from the cells in the terminal portion of these glands' ducts. This part of the sweat gland duct is termed the acrosyringium and had led to grouping poromas in the acrospiroma class of skin tumors. Here, poromas are regarded as distinct sweat gland tumors that differ from other sweat gland tumors by their characteristic clinical presentations, microscopic histopathology, and the genetic mutations that their neoplastic cells have recently been found to carry.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

<span class="mw-page-title-main">Malignant chondroid syringoma</span> Type of skin cancer

A malignant chondroid syringoma is a very uncommon cutaneous (skin) condition characterised by an adnexal eccrine tumour.

<span class="mw-page-title-main">Microcystic adnexal carcinoma</span> Medical condition

Microcystic adnexal carcinoma (MAC) is a rare sweat gland cancer, which often appears as a yellow spot or bump in the skin. It usually occurs in the neck or head, although cases have been documented in other areas of the body. Most diagnosis occur past the age of 50. Although considered an invasive cancer, metastasis rarely occurs. If the tumor spreads, it can grow and invade fat, muscles, and other types of tissue. Main treatments are wide local excision or Mohs micrographic surgery, which ensures that most, if not all, cancer cells are removed surgically.

<span class="mw-page-title-main">Eccrine carcinoma</span> Medical condition

Eccrine carcinoma is a rare skin condition characterized by a plaque or nodule on the scalp, trunk, or extremities. It originates from the eccrine sweat glands of the skin, accounting for less than 0.01% of diagnosed cutaneous malignancies. Eccrine carcinoma tumors are locally aggressive, with a high rate of recurrence. Lack of reliable immunohistochemical markers and similarity to other common tumors has made identification of eccrine carcinoma difficult.

<span class="mw-page-title-main">Acrospiroma</span> Medical condition

Acrospiromas are a broad class of benign cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Acrospiromas are thought to derive from apocrine or eccrine sweat gland ducts near their acrosyringium, i.e. point where these ducts open to the skin's surface.

Epstein–Barr virus–associated lymphoproliferative diseases are a group of disorders in which one or more types of lymphoid cells, i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV). This causes the infected cells to divide excessively, and is associated with the development of various non-cancerous, pre-cancerous, and cancerous lymphoproliferative disorders (LPDs). These LPDs include the well-known disorder occurring during the initial infection with the EBV, infectious mononucleosis, and the large number of subsequent disorders that may occur thereafter. The virus is usually involved in the development and/or progression of these LPDs although in some cases it may be an "innocent" bystander, i.e. present in, but not contributing to, the disease.

Ovarian germ cell tumors (OGCTs) are heterogeneous tumors that are derived from the primitive germ cells of the embryonic gonad, which accounts for about 2.6% of all ovarian malignancies. There are four main types of OGCTs, namely dysgerminomas, yolk sac tumor, teratoma, and choriocarcinoma.

CYLD cutaneous syndrome (CCS) encompasses three rare inherited cutaneous adnexal tumor syndromes: multiple familial trichoepithelioma (MFT1), Brooke–Spiegler syndrome (BSS), and familial cylindromatosis (FC). Cutaneous adnexal tumors are a large group of skin tumors that consist of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. CCS tumors are hair follicle tumors.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

References

  1. ↑ Zaballos P, Gómez-Martín I, Martin JM, Bañuls J (October 2018). "Dermoscopy of Adnexal Tumors". Dermatologic Clinics. 36 (4): 397–412. doi:10.1016/j.det.2018.05.007. PMID   30201149. S2CID   52185272.
  2. 1 2 3 Sellheyer K (February 2015). "Spiradenoma and cylindroma originate from the hair follicle bulge and not from the eccrine sweat gland: an immunohistochemical study with CD200 and other stem cell markers". Journal of Cutaneous Pathology. 42 (2): 90–101. doi:10.1111/cup.12406. PMID   25354097. S2CID   25569722.
  3. 1 2 3 4 Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P (May 2021). "Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation". International Journal of Molecular Sciences. 22 (10): 5077. doi: 10.3390/ijms22105077 . PMC   8151110 . PMID   34064849.
  4. 1 2 Macagno N, Sohier P, Kervarrec T, Pissaloux D, Jullie ML, Cribier B, Battistella M (January 2022). "Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors". Cancers. 14 (3): 476. doi: 10.3390/cancers14030476 . PMC   8833812 . PMID   35158743.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 Wagner K, Jassal K, Lee JC, Ban EJ, Cameron R, Serpell J (October 2021). "Challenges in diagnosis and management of a spiradenocarcinoma: a comprehensive literature review". ANZ Journal of Surgery. 91 (10): 1996–2001. doi:10.1111/ans.16626. PMID   33522696. S2CID   231767765.
  6. 1 2 3 4 5 6 7 8 9 Andreoli MT, Itani KM (May 2011). "Malignant eccrine spiradenoma: a meta-analysis of reported cases". American Journal of Surgery. 201 (5): 695–9. doi:10.1016/j.amjsurg.2010.04.015. PMID   20851376.
  7. ↑ Chauhan DS, Guruprasad Y (January 2012). "Dermal cylindroma of the scalp". National Journal of Maxillofacial Surgery. 3 (1): 59–61. doi: 10.4103/0975-5950.102163 . PMC   3513812 . PMID   23251061.
  8. ↑ Kazakov DV, Zelger B, Rütten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M (May 2009). "Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome". The American Journal of Surgical Pathology. 33 (5): 705–19. doi:10.1097/PAS.0b013e3181966762. PMID   19194280. S2CID   9858971.
  9. 1 2 3 4 5 6 Nagy N, Dubois A, Szell M, Rajan N (2021). "Genetic Testing in CYLD Cutaneous Syndrome: An Update". The Application of Clinical Genetics. 14: 427–444. doi: 10.2147/TACG.S288274 . PMC   8566010 . PMID   34744449.
  10. 1 2 Gordon S, Styron BT, Haggstrom A (2013). "Pediatric segmental eccrine spiradenomas: a case report and review of the literature". Pediatric Dermatology. 30 (6): e285–6. doi:10.1111/j.1525-1470.2012.01777.x. PMID   22612572. S2CID   46430687.
  11. 1 2 3 4 5 6 7 Ren F, Hu Z, Kong Q, Sang H (August 2015). "Multiple Segmental Eccrine Spiradenoma with a Zosteriform Pattern: A Case Report and Literature Review". Annals of Dermatology. 27 (4): 435–8. doi:10.5021/ad.2015.27.4.435. PMC   4530155 . PMID   26273161.
  12. 1 2 3 4 5 Li Z, Li G, Jiang X, Fu X (April 2021). "Giant vascular eccrine spiradenoma: the first case in the scrotum and review of the literature author". Diagnostic Pathology. 16 (1): 37. doi: 10.1186/s13000-021-01073-8 . PMC   8091673 . PMID   33941210.
  13. ↑ Heller DS (September 2015). "Benign Tumors and Tumor-like Lesions of the Vulva". Clinical Obstetrics and Gynecology. 58 (3): 526–35. doi:10.1097/GRF.0000000000000133. PMID   26125957. S2CID   11112420.
  14. ↑ Metovic J, Gallino C, Zanon E, Bussone R, Russo R, Vissio E, Annaratone L, Conti L, Papotti M, Cassoni P, Castellano I (August 2019). "Eccrine spiradenoma of the nipple: Case report, differential diagnosis and literature review". Histology and Histopathology. 34 (8): 909–915. doi:10.14670/HH-18-094. PMID   30806477.
  15. ↑ Avraham JB, Villines D, Maker VK, August C, Maker AV (July 2013). "Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes". Journal of Surgical Oncology. 108 (1): 57–62. doi:10.1002/jso.23346. PMID   23677677. S2CID   27443162.
  16. 1 2 3 4 5 Huang A, Vyas NS, Mercer SE, Phelps RG (April 2019). "Histological findings and pathologic diagnosis of spiradenocarcinoma: A case series and review of the literature". Journal of Cutaneous Pathology. 46 (4): 243–250. doi:10.1111/cup.13408. PMID   30588645. S2CID   58592021.
  17. 1 2 3 Plotzke JM, Adams DJ, Harms PW (January 2022). "Molecular pathology of skin adnexal tumours". Histopathology. 80 (1): 166–183. doi:10.1111/his.14441. hdl: 2027.42/171211 . PMID   34197659. S2CID   235714739.
  18. 1 2 Staiger RD, Helmchen B, Papet C, Mattiello D, Zingg U (October 2017). "Spiradenocarcinoma: A Comprehensive Data Review" (PDF). The American Journal of Dermatopathology. 39 (10): 715–725. doi:10.1097/DAD.0000000000000910. PMID   28570391. S2CID   41154006.
  19. 1 2 3 4 Held L, Ruetten A, Saggini A, Kempter W, Tiedke C, Weber-Kuhn S, De Saint Aubain N, Mentzel T (March 2021). "Metaplastic spiradenocarcinoma: Report of two cases with sarcomatous differentiation". Journal of Cutaneous Pathology. 48 (3): 384–389. doi:10.1111/cup.13897. PMID   33051901. S2CID   222352535.
  20. 1 2 Rashid M, van der Horst M, Mentzel T, Butera F, Ferreira I, Pance A, Rütten A, Luzar B, Marusic Z, de Saint Aubain N, Ko JS, Billings SD, Chen S, Abi Daoud M, Hewinson J, Louzada S, Harms PW, Cerretelli G, Robles-Espinoza CD, Patel RM, van der Weyden L, Bakal C, Hornick JL, Arends MJ, Brenn T, Adams DJ (May 2019). "ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma". Nature Communications. 10 (1): 2213. Bibcode:2019NatCo..10.2213R. doi:10.1038/s41467-019-09979-0. PMC   6525246 . PMID   31101826.
  21. ↑ Lork M, Verhelst K, Beyaert R (July 2017). "CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different". Cell Death and Differentiation. 24 (7): 1172–1183. doi:10.1038/cdd.2017.46. PMC   5520167 . PMID   28362430.
  22. ↑ Vlahopoulos SA (August 2017). "Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode". Cancer Biology & Medicine. 14 (3): 254–270. doi:10.20892/j.issn.2095-3941.2017.0029. PMC   5570602 . PMID   28884042.
  23. ↑ Cui Z, Kang H, Grandis JR, Johnson DE (January 2021). "CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers". Molecular Cancer Research. 19 (1): 14–24. doi:10.1158/1541-7786.MCR-20-0565. PMC   7840145 . PMID   32883697.
  24. ↑ Wargo JJ, Carr DR, Plaza JA, Verschraegen CF (February 2022). "Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition". Journal of the National Comprehensive Cancer Network. 20 (4): 318–320. doi: 10.6004/jnccn.2021.7119 . PMID   35196645. S2CID   247082711.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.